Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Pancreatic Neoplasms 1Multiple Myeloma 1Breast Neoplasms 1Breast Diseases 1

Interventions

Dexamethasone 114daratumumab 68Lenalidomide 66Bortezomib 55pomalidomide 44carfilzomib 39Cyclophosphamide 33Specimen Handling 30Calcium Dobesilate 30Biopsy 27Magnetic Resonance Spectroscopy 24belantamab mafodotin 20isatuximab 19fludarabine 17talquetamab 16iberdomide 15Melphalan 15dexamethasone acetate 13dexamethasone 21-phosphate 13auricularum 13fludarabine phosphate 11selinexor 10elotuzumab 10tocilizumab 9X-Rays 8Nivolumab 8Sirolimus 7trametinib 6Whole-Body Irradiation 6Mycophenolic Acid 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Leflunomide × 90 days × Clear all
NCT04508790 2026-05-29

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

City of Hope Medical Center

Phase 2 Recruiting
29 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡